{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:28:01Z","timestamp":1760189281069},"reference-count":35,"publisher":"Japanese Pharmacological Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharmacol Sci"],"published-print":{"date-parts":[[2012]]},"DOI":"10.1254\/jphs.12114fp","type":"journal-article","created":{"date-parts":[[2012,10,29]],"date-time":"2012-10-29T23:49:44Z","timestamp":1351554584000},"page":"206-212","source":"Crossref","is-referenced-by-count":2,"title":["Acute Vasoreactivity Testing With Nicardipine in Patients With Pulmonary Arterial Hypertension"],"prefix":"10.1254","volume":"120","author":[{"given":"Yukihiro","family":"Saito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazufumi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsumasa","family":"Miyaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Akagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Mizoguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiko","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soichiro","family":"Fuke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Fujio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiko","family":"Kiyooka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Nagase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihisa","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo F","family":"Kusano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"332","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-10-0190"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.12R01CR"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 De Feyter PJ, Kerkkamp HJ, de Jong JP. Sustained beneficial effect of nifedipine in primary pulmonary hypertension. Am Heart J. 1983;105:333–334.","DOI":"10.1016\/0002-8703(83)90539-2"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Saito D, Haraoka S, Yoshida H, Kusachi S, Yasuhara K, Nishihara M, et al. Primary pulmonary hypertension improved by long-term oral administration of nifedipine. Am Heart J. 1983;105:1041–1042.","DOI":"10.1016\/0002-8703(83)90414-3"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76–81.","DOI":"10.1056\/NEJM199207093270203"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.488486"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Partanen J, Nieminen MS, Luomanmaki K. Death in a patient with primary pulmonary hypertension after 20 mg of nifedipine. N Engl J Med. 1993;329:812–813.","DOI":"10.1056\/NEJM199309093291117"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Barst RJ, Gibbs JSR, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:S78–S84.","DOI":"10.1016\/j.jacc.2009.04.017"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Morales-Blanhir J, Santos S, de Jover L, Sala E, Pare C, Roca J, et al. Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension. Respir Med. 2004;98:225–234.","DOI":"10.1016\/j.rmed.2003.09.019"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)92033-X"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Rubin LJ, Groves BM, Reeves JT, Frosolono M, Handel F, Cato AE. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation. 1982;66:334–338.","DOI":"10.1161\/01.CIR.66.2.334"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Schrader BJ, Inbar S, Kaufmann L, Vestal RE, Rich S. Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. J Am Coll Cardiol. 1992;19:1060–1064.","DOI":"10.1016\/0735-1097(92)90295-X"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.674002"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:S20–S31.","DOI":"10.1016\/j.jacc.2009.04.018"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Landmark K, Refsum AM, Simonsen S, Storstein O. Verapamil and pulmonary hypertension. Acta Med Scand. 1978;204:299–302.","DOI":"10.1111\/j.0954-6820.1978.tb08443.x"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.98.12020265"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425–1436.","DOI":"10.1056\/NEJMra040291"},{"key":"18","unstructured":"18 Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493–2537."},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-10-0671"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Hashimoto K, Nakamura K, Fujio H, Miyaji K, Morita H, Kusano K, et al. Epoprostenol therapy decreases elevated circulating levels of monocyte chemoattractant protein-1 in patients with primary pulmonary hypertension. Circ J. 2004;68:227–231.","DOI":"10.1253\/circj.68.227"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007;131:1917–1928.","DOI":"10.1378\/chest.06-2674"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq170"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2009.11.015"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Sitbon O, Brenot F, Denjean A, Bergeron A, Parent F, Azarian R, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med. 1995;151:384–389.","DOI":"10.1164\/ajrccm.151.2.7842196"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Nootens M, Schrader B, Kaufmann E, Vestal R, Long W, Rich S. Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. Chest. 1995;107:54–57.","DOI":"10.1378\/chest.107.1.54"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2009.11.010"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Packer M, Medina N, Yushak M, Wiener I. Detrimental effects of verapamil in patients with primary pulmonary hypertension. Br Heart J. 1984;52:106–111.","DOI":"10.1136\/hrt.52.1.106"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Crevey BJ, Dantzker DR, Bower JS, Popat KD, Walker SD. Hemodynamic and gas exchange effects of intravenous diltiazem in patients with pulmonary hypertension. Am J Cardiol. 1982;49:578–583.","DOI":"10.1016\/S0002-9149(82)80015-5"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(83)80035-6"},{"key":"30","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(84)80048-0"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(81)90069-1"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Bristow MR, Ginsburg R, Laser JA, McAuley BJ, Minobe W. Tissue response selectivity of calcium antagonists is not due to heterogeneity of [3H]-nitrendipine binding sites. Br J Pharmacol. 1984;82:309–320.","DOI":"10.1111\/j.1476-5381.1984.tb10765.x"},{"key":"33","unstructured":"33 Kumada T, Kawai C, Sasayama S, Kinoshita M, Kawamura K, Kusukawa R, et al. [Clinical efficacy of nicardipine by intravenaous infusion in patients with acute heart gailure. A multicenter randomized double-blind placebo-controlled trial.] Jpn Pharmacol Ther. 1995;23:375–398. (text in Japanese with English abstract)"},{"key":"34","unstructured":"34 Kinoshita M, Kawai C, Kumada T, Kawamura K, Kusukawa R. [Acute effects of a single dose of intravenous administration of nicardipine hydrochloride in patients with acute heart failure.] Early phase II study. Jpn Pharmacol Ther. 1995;23:345–356. (text in Japanese with English abstract)"},{"key":"35","unstructured":"35 Hirota Y, Kawai C, Hori R, Okumura K, Kinoshita M, Kumada T, et al. [Intravenous nicardipine infusion for the treatment of acute heart failure. A double blind study for the optimal dose determination (late phase II study).] Jpn Pharmacol Ther. 1995;23:357–373. (text in Japanese with English abstract)"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T15:09:40Z","timestamp":1621436980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jphs\/120\/3\/120_12114FP\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1254\/jphs.12114fp","relation":{},"ISSN":["1347-8613","1347-8648"],"issn-type":[{"value":"1347-8613","type":"print"},{"value":"1347-8648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}